Exploring Reasonable Extension of Secukinumab Dosing Intervals in Real-World Settings
收藏NIAID Data Ecosystem2026-05-10 收录
官方服务：
资源简介：
Supplemental material for "Exploring Reasonable Extension of Secukinumab Dosing Intervals in Real-World Settings".
应用场景：
创建时间：
2025-11-05
相关数据集
Autoimmune Disease Therapeutics Market by Drug Class (Immunosuppressants, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, and Biologics), By Distribution Channel (Hospitals, Clinics, Drug Stores, and Independent Pharmacies), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028
In 2021, the global autoimmune disease therapeutics market size was valued $54.8 billion. By 2028, it is expected to reach $113.48 billion, growing at 12.9%.
www.zionmarketresearch.com2024-12-03 更新180
Pharmacologically enhanced regulatory hematopoietic stem cells (HSC.Regs) reverts experimental autoimmune diabetes. Pharmacologically enhanced regulatory hematopoietic stem cells (HSC.Regs) reverts experimental autoimmune diabetes
Ex-vivo pharmacological modulation enhances the immunoregulatory and trafficking properties of HSCs which mitigated autoimmune diabetes and other autoimmune disorders. We used GeneChip microarrays to
NIAID Data Ecosystem50
The effect of treatment with the helminth product Tuftsin-phosphorylcholine (TPC) on the microbiome of mice with active lupus
The hygiene hypothesis claims that lack of exposure to microorganisms in developed countries, correlates with increased incidence of autoimmune diseases. It was also found that helminths are able to m
NIAID Data Ecosystem40
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which p
Figshare2016-02-13 更新70
Selective JAK1 inhibitors and the therapeutic applications thereof: a patent review (2016–2023)
The family of Janus kinases (JAKs) consists of four intracellular non-receptor tyrosine kinases: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Among these four subtypes, JAK1 is the only isoform tha
Taylor & Francis Group2025-02-01 更新40
